Nvidia Partners with Droplet Biosciences to Enhance AI in Cancer Diagnostics
Nvidia collaborates with Droplet Biosciences to improve lymph-based liquid biopsy testing using its AI infrastructure, Parabricks. The partnership significantly reduces genomic data analysis times, with variant calling cut from 36 hours to under three hours and overall analysis from 10 days to two days. Nvidia's recent collaborations include partnerships with Eli Lilly, J&J MedTech, Innovaccer, and Diligent Robotics, as it aims to strengthen its presence in the medtech sector.
Theia Market Signal Identification - AI Assisted
Nvidia is expanding its involvement in medtech and cancer research by partnering with Droplet Biosciences, which specializes in lymph-based liquid biopsy testing. Using Nvidia's AI infrastructure, Parabricks, Droplet has achieved a reduction in genomic data analysis times: variant calling decreased from 36 hours to under three hours, sequence alignment from 10 hours to under one hour, and overall analysis from 10 days to two days. This collaboration is part of Nvidia's broader strategy to form partnerships within the healthcare sector, which includes initiatives with Eli Lilly, J&J MedTech, Innovaccer, and Diligent Robotics, as well as a partnership with Oracle and the Department of Energy to develop AI supercomputers for scientific discovery.
Comments